Allogene Therapeutics
Anita Bawa is a seasoned quality management professional with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as the Quality Site Head at Allogene Therapeutics since September 2019, Anita leads the quality organization at a manufacturing facility in Newark, CA, overseeing various quality functions and preparing for regulatory inspections. Prior to this role, Anita held key positions such as Head of Quality Control and Compliance Strategic Initiatives at Sutro Biopharma and Head of Quality Control at Bayer Pharmaceuticals, where responsibilities included managing large teams, ensuring compliance with industry regulations, and leading significant quality projects. Additionally, Anita has a background in quality management from Genentech, highlighting a consistent focus on process improvement and regulatory compliance throughout a career spanning several leadership roles. Anita holds an M.B.A. from the University of San Francisco and a Bachelor’s Degree in Business from Saint Mary's College of California.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.